Rare diseases

Sharing the mission to conquer rare diseases

Closer collaboration between pharmaceutical companies and patient organizations will accelerate drug development At an ever-quickening pace, biopharmaceutical companies and patient advocacy groups are banding together to hasten development of new drugs for rare diseases. Advocacy groups rely on their partners for financial and scientific support while providing access to repositories of patient data – the key to understanding rare diseases …

BioPharma Mexico is where experts like Shire Mexico meet to network, learn from each other, and discuss the latest developments in biopharma.

What Does Shire Mexico Have to Say About Orphan Drugs?

We’re excited to announce that Raul Vivar, General Director of Shire Mexico, will be speaking at this year’s BioPharma Mexico. Raul’s presentation is titled “Accessing public institutions: A success story changing the lives of lysosomal disease patients”, and will take place at 4:05 pm on Wednesday, November 5th. Don’t miss it! Download our interview with Raul here During his presentation, …

BioPharma México es donde van expertos cómo BioMarin Pharmaceutical para network, aprender del otro, y discutir los desarrollos recientes de la industria biofarmacéutica de México.

BioMarin Pharmaceutical Comparte su Sabiduría de la Industria Biofarmacéutica de México

Es un placer contar con la participacion de David López, Country Manager México de BioMarin Pharmaceutical, como uno de nuestros ponentes en BioPharma México 2014. Tuvimos el placer de entrevistar a David antes del evento y le preguntamos varias cuestiones sobre el estatus de las enfermedades raras en México que te darán una mejor idea de cómo funciona la industria. …

Been a Partner? What’s Your #PartneringPetPeeve?

In the Pharmaceutical and Biotech industries, partnering and collaborations are a frequent occurrence. Usually, a larger company will utilize a more niche company as a partner for a specific function (CROs and CMOs), or find a smaller drug discovery company that has a compound of interest. This is particularly true in the Orphan Drug industry, where small pharma companies are …

The World Orphan Drug Congress USA is where pharma, government, and patient groups gather to network, learn from each other, and discuss the latest orphan drug and rare disease strategies and technologies.

The Role of Specialty Pharmacy in Orphan Drug Therapy

Orsini Healthcare is a leading national specialty pharmacy focused on the delivery of specialty medications to patients with rare conditions. Their disease-specific clinical CareTeam programs, commitment to high-touch customer service, and our patient centered approach ensures satisfaction and adherence to treatment. Orsini Healthcare will be exhibiting at this year’s World Orphan Drug Congress USA, and we were lucky enough to …

The World Orphan Drug Congress is where the orphan drug industry goes to network, learn from each other, and discuss the latest strategies and technology.

The Role of Big Pharma in Orphan Drug Development and Commercialization

Orphan drug development is often perceived as being done by small biotech companies. However, most big pharmaceutical companies are heavily invested in the rare disease community. In this exclusive interview with Rare Disease Report, Bert Bruce, Vice President of Rare Disease Commercial Development at Pfizer Inc, previews his presentation at the upcoming World Orphan Drug Congress USA 2014 being held …

Closer ties for EU & Australia in Orphan Drugs

The European Medicines Agency (EMA) and Australia’s Therapeutic Goods Administration (TGA) have announced, at a collaboration meeting in London, that they are to share the full assessment reports related to marketing authorisations (MA) for orphan drugs. According to EMA executive director Professor Guido Rasi and Professor John Skerritt, national manager of the TGA, this will lead to greater scientific exchange when …

Growth of orphan drug market puts the World Orphan Drug Congress USA in the spotlight

Differently from the uncertainty of the economic growth across developed countries, the pharmaceutical industry is optimistic about the increasing revenue from orphan drug development. In a recent report conducted by BCC Research, the orphan drug market in 2012 was evaluated in $82 billion and is expected to grow at an average rate of 5.4% in the next five years, to …